Dissecting the role of inflammatory biomarkers in breast cancer: Insights from Mendelian randomization

剖析炎症生物标志物在乳腺癌中的作用:来自孟德尔随机化的启示

阅读:2

Abstract

Inflammatory biomarkers (including C-reactive protein [CRP], interleukin-6 [IL-6], procalcitonin [PCT], and serum amyloid A [SAA]) have been postulated to influence tumorigenesis, yet their causal relevance to breast cancer (BC) remains uncertain. We applied a two-sample Mendelian randomization (MR) framework to evaluate putative causal relationships between these circulating inflammatory factors and BC risk. Publicly available genome-wide association study summary statistics were used to identify, curate, and clump single-nucleotide polymorphisms that robustly trace CRP, IL-6, PCT, and SAA concentrations, which then served as instrumental variables. Causal estimates were generated with inverse-variance weighting, MR-Egger regression, weighted-median, simple-mode, and weighted-mode models. Heterogeneity was assessed by Cochran Q statistic, horizontal pleiotropy by the MR-Egger intercept, and robustness by leave-one-out as well as funnel-plot inspection. Two-sample MR demonstrated that genetically predicted SAA is positively associated with BC risk (inverse-variance weighting odds ratios = 1.002, 95% confidence interval 1.000-1.003, P = .023), whereas CRP, IL-6, and PCT exhibited no evidence of causal effects on BC in any MR model. Sensitivity analyses showed no substantial heterogeneity or directional pleiotropy, and causal estimates were stable after sequential SNP exclusion. In summary, the present MR study provides genetic evidence that elevated SAA causally increases the risk of developing BC, whereas CRP, IL-6, and PCT do not appear to exert independent causal influences.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。